Health

STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 07/10/2026, 21:21:26 UTC.

Briefings

The Department of Justice issued a new directive targeting drugmakers under the Federal Food, Drug, and Cosmetic Act, expanding jurisdiction from healthcare providers to pharmaceutical manufacturers. Kevin Lowell, a former DOJ deputy chief, noted this represents a significant expansion of the agency's crosshairs in the life sciences sector.

Key points

• The DOJ's National Fraud Enforcement Division explicitly includes the Federal Food, Drug, and Cosmetic Act in its directive against fraud.
• Kevin Lowell, a former deputy chief in the health care fraud section, stated this is a significant expansion of the agency's jurisdiction.

Context

The National Fraud Enforcement Division typically pursues health fraud cases centered on providers, clinics, and home health agencies. This directive marks a shift toward targeting drug and device makers, with the Federal Food, Drug, and Cosmetic Act now explicitly included in the enforcement scope.

Limitations

The evidence is a single article from October 2026. It does not provide specific dates of the directive's implementation, exact numbers of targeted companies, or specific case outcomes. The statement from Kevin Lowell is a paraphrase and does not include direct quotes or verified statistics.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/10/2026, 03:08:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiewyfnjuvuduc4vtot376hebfituwspkflrdurzru6p5b6jilymdq